Allergan Inc.: Company Analysis (Strategy, Portfolio and Pipeline Analysis) e

• Publication date: November 2010

About This Report This analysis examines the historical and projected performance for Allergan in the prescription pharmaceutical segment . The report includes global corporate vision and strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year revenue projections for key drugs. What's Included in This Report? * Get detailed data into Allergan's strategic vision acro...

About This Report

This analysis examines the historical and projected performance for Allergan in the prescription pharmaceutical segment . The report includes global corporate vision and strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year revenue projections for key drugs.

What's Included in This Report?


* Get detailed data into Allergan's strategic vision across the next 6 years
* Analyze firm revenue projections by product, therapy area, lifecycle stage, geography, molecule type and source

Key Market Facts

Strategic insight into the prospects for Allergan over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the firm 's prescription pharmaceuticals outlook using a variety of cuts of the historical and projection sales.

Why Should You Buy This Report?


* Compare Allergan's performance against key competitors in the prescription pharmaceutical segment
* Understand how Allergan has exploited side effects and cross-marketing opportunities to maximize returns from its specialist sales force
* Get detailed data into how re-formulations of existing brands are not expected to be sufficient to maintain sales growth in the tight ophthalmic space

Ophthalmic Devices Industry

Summary
Main Facts
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Allergan: PharmaVitae projections at a glance
Strategic insight
Botox plays a central role in Allergan’s synergistic expansion
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Firms Introduction
Firms sales
Firms financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
COMPANY Introduction
Main Facts
Background
Key corporate developments
Merger and Acquisition history
Acquired by SmithKline Beckman
Allergan spun-out from SmithKline Beckman
Acquisition of Oculinum
Divestment of Allergan Humphrey
Divestment of contact lens businesses
Five take over s were made in and around 1995
Allergan Specialty Therapeutics spun-out
Allergan Specialty Therapeutics re-acquired
Bardeen Sciences set-up
Advanced Medical Optics spun-out
Bardeen Sciences take over d
Oculex take over d
Acquistition of Inamed
Groupe Corneal Laboratoires take over d
EndoArt take over d
Acquisition of Esprit Pharma
Acquisition of Serica Technologies
Current company organisation
Pharmaceuticals
Allergan Medical
COMPANY REVENUES
Main Facts
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Portfolio overview
Portfolio overview, 2003–09
Portfolio overview, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
New Product Analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Main Facts
Note regarding full-year 2010 financial data
Reconciliation between PharmaVitae-formatted prescription pharma sales and firm -reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key product overview
Botox
Restasis
Lumigan franchise
Alphagan franchise
Ozurdex
Latisse
APPENDIX
References
Research and Development pipeline
Abbreviations
Exchange rates